Zobrazeno 1 - 9
of 9
pro vyhledávání: '"Karolyn K. Morris"'
Autor:
Heather A. Rasmussen, Sandra Kanan, Hilary Coye, Andrew J. Cowan, Edward N. Libby, Jonathan R. Fromm, Chaitra S. Ujjani, Ryan C. Lynch, Mazyar Shadman, Mary Philip, Sanaz Behnia, Edus H. Warren, Stephen D. Smith, Margaret E. Nartea, Ryan D. Cassaday, Andrei R. Shustov, Karolyn K. Morris, Christen N. Martino, Jenna M. Voutsinas, Brian G. Till, Ajay K. Gopal
Publikováno v:
Blood. 136:16-18
Background: Classical Hodgkin lymphoma (CHL) patients (pts) requiring second line therapy may still be cured with multiagent salvage chemotherapy followed by autologous stem cell transplant (ASCT). The likelihood of long-term remission following ASCT
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::823f974d9948a29958e750103d2509d7
https://doi.org/10.1182/blood-2020-133763
https://doi.org/10.1182/blood-2020-133763
Autor:
John Madrigal, Brian R. Wolf, Jordan R. McKenzie, Jonathan W. Goldman, Blanca A. Ledezma, Carlos R. Adame, Karolyn K. Morris, Narek Shaverdian, Edward B. Garon, Danielle J. Nameth, Sitaram Vangala, Marshall L. Spiegel, Phillip A. Abarca, Nima Moghadam, Caitlin Marx, D. Andrew Tucker, Paulina J Linares, Aaron Lisberg, Ariana R. Hardy, Courtney L. Wells, Krikor Bornazyan, Natalie Chong, Jaime Hunt, Melody A. Mendenhall, James M. Carroll, David Elashoff
Publikováno v:
Cancer immunology research, vol 6, iss 3
We retrospectively analyzed non–small cell lung cancer (NSCLC) patients from a single center treated with pembrolizumab on the KEYNOTE-001 trial and evaluated the association between treatment-related adverse events (trAEs) and clinical outcomes. I
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::892379ff4fab2855f5d9e6131ca784d6
https://europepmc.org/articles/PMC6066474/
https://europepmc.org/articles/PMC6066474/
Autor:
Lorinda Soma, Karolyn K. Morris, Ajay K. Gopal, Stephen D. Smith, Sandra Kanan, Solomon A. Graf, Ryan C. Lynch, Sanaz Behnia, Jenna M. Voutsinas, Qian Vicky Wu, Thomas R. Chauncey, Ryan D. Cassaday, Heather A. Rasmussen, Elizabeth F. Krakow
Publikováno v:
Blood. 134:1596-1596
Background : Relapsed or refractory (R/R) transformed indolent B-cell non-Hodgkin lymphoma (iB-NHL) is an uncommon clinical entity associated with poor prognosis. Unfortunately, most trials of aggressive B-NHL tend to specifically exclude transformed
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::8a01e7e861a7acc1ca681d86b4557e4d
https://doi.org/10.1182/blood-2019-126086
https://doi.org/10.1182/blood-2019-126086
Autor:
Solomon A. Graf, Lorinda Soma, Ajay K. Gopal, Sandra Kanan, Karolyn K. Morris, Stephen D. Smith, Thomas R. Chauncey, Ryan D. Cassaday, Pamela S. Becker, Heather A. Rasmussen
Publikováno v:
Blood. 132:2954-2954
Background Relapsed or refractory (R/R) transformed indolent B-cell non-Hodgkin lymphoma (iB-NHL) is associated with a poor prognosis. Unfortunately, there is little prospective data using novel agents, including kinase inhibitors, since trials tend
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::0deefec6280bd89e088dec7ebcdca0e3
https://doi.org/10.1182/blood-2018-99-115476
https://doi.org/10.1182/blood-2018-99-115476
Autor:
Blanca A. Ledezma, Jonathan W. Goldman, Alice Huai-Yu Li, Meghan Brennan, Karolyn K. Morris, Melody A. Mendenhall, Lauren Sauer, Deborah Jean Lee Wong, James M. Carroll, D. Andrew Tucker, Paulina J Linares, Marshall L. Spiegel, Edward B. Garon, Carlos R. Adame, Courtney L. Wells, Jennifer L. Strunck, Sina Famenini, Christina DiLauro Abaya, Ariana R. Hardy, Aaron Lisberg
Publikováno v:
Journal of Clinical Oncology. 34:e20662-e20662
e20662Background: The 6 FDA drug approvals for non-small cell lung cancer (NSCLC) in 2015 included 2 programmed cell death protein 1 (PD-1) inhibitors and a 3rd generation (gen) epidermal growth fa...
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::521125bf8d15152f4ac04e8b48b10a6f
https://doi.org/10.1200/jco.2016.34.15_suppl.e20662
https://doi.org/10.1200/jco.2016.34.15_suppl.e20662
Autor:
Lynch RC; Division of Medical Oncology, University of Washington, Seattle, WA.; Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA., Poh C; Division of Medical Oncology, University of Washington, Seattle, WA., Ujjani CS; Division of Medical Oncology, University of Washington, Seattle, WA.; Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA., Warren EH; Division of Medical Oncology, University of Washington, Seattle, WA.; Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA., Smith SD; Division of Medical Oncology, University of Washington, Seattle, WA.; Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA., Shadman M; Division of Medical Oncology, University of Washington, Seattle, WA.; Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA., Morris K; Division of Medical Oncology, University of Washington, Seattle, WA., Lee S; Division of Medical Oncology, University of Washington, Seattle, WA., Rasmussen H; Division of Medical Oncology, University of Washington, Seattle, WA., Ottemiller S; Division of Medical Oncology, University of Washington, Seattle, WA., Shelby M; Division of Medical Oncology, University of Washington, Seattle, WA., Keo S; Division of Medical Oncology, University of Washington, Seattle, WA., Verni K; Division of Medical Oncology, University of Washington, Seattle, WA., Kurtz DM; Division of Oncology, Stanford University, Stanford, CA., Alizadeh AA; Division of Oncology, Stanford University, Stanford, CA., Chabon JJ; Foresight Diagnostics, Aurora, CO., Hogan GJ; Foresight Diagnostics, Aurora, CO., Schulz A; Foresight Diagnostics, Aurora, CO., Gooley T; Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA., Voutsinas JM; Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA., Gopal AK; Division of Medical Oncology, University of Washington, Seattle, WA.; Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA.
Publikováno v:
Blood advances [Blood Adv] 2023 Jun 13; Vol. 7 (11), pp. 2449-2458.
Autor:
Lynch RC; Department of Medicine, Division of Medical Oncology, University of Washington, Seattle, WA, USA; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA., Cassaday RD; Department of Medicine, Division of Hematology, University of Washington, Seattle, WA, USA; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA., Smith SD; Department of Medicine, Division of Medical Oncology, University of Washington, Seattle, WA, USA; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA., Fromm JR; Department of Laboratory Medicine, University of Washington, Seattle, WA, USA., Cowan AJ; Department of Medicine, Division of Medical Oncology, University of Washington, Seattle, WA, USA; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA., Warren EH; Department of Medicine, Division of Medical Oncology, University of Washington, Seattle, WA, USA; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA., Shadman MS; Department of Medicine, Division of Medical Oncology, University of Washington, Seattle, WA, USA; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA., Shustov A; Department of Medicine, Division of Medical Oncology, University of Washington, Seattle, WA, USA; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA., Till BG; Department of Medicine, Division of Medical Oncology, University of Washington, Seattle, WA, USA; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA., Ujjani CS; Department of Medicine, Division of Medical Oncology, University of Washington, Seattle, WA, USA; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA., Libby EN 3rd; Department of Medicine, Division of Medical Oncology, University of Washington, Seattle, WA, USA; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA., Philip M; Department of Medicine, Division of Hematology and Oncology, Vanderbilt University Medical Center, Nashville, TN, USA., Coye H; Seattle Cancer Care Alliance, Seattle, WA, USA., Martino CN; Seattle Cancer Care Alliance, Seattle, WA, USA., Bhark SL; Seattle Cancer Care Alliance, Seattle, WA, USA., Morris K; Department of Medicine, Division of Medical Oncology, University of Washington, Seattle, WA, USA., Rasmussen H; Department of Medicine, Division of Medical Oncology, University of Washington, Seattle, WA, USA., Behnia S; Department of Radiology, University of Washington, Seattle, WA, USA., Voutsinas J; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA., Gopal AK; Department of Medicine, Division of Medical Oncology, University of Washington, Seattle, WA, USA; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA. Electronic address: agopal@uw.edu.
Publikováno v:
The Lancet. Haematology [Lancet Haematol] 2021 Aug; Vol. 8 (8), pp. e562-e571.
Autor:
Graf SA; Division of Medical Oncology, University of Washington Medicine, Seattle, WA; Clinical Research Division, Fred Hutch Cancer Research Center, Seattle, WA; Department of Hospital and Specialty Medicine, Veterans Affairs Puget Sound Health Care System, Seattle, WA., Cassaday RD; Clinical Research Division, Fred Hutch Cancer Research Center, Seattle, WA; Division of Hematology., Morris K; Division of Medical Oncology, University of Washington Medicine, Seattle, WA., Voutsinas JM; Clinical Research Division, Fred Hutch Cancer Research Center, Seattle, WA., Wu QV; Clinical Research Division, Fred Hutch Cancer Research Center, Seattle, WA., Behnia S; Division of Nuclear Medicine, Department of Radiology., Lynch RC; Division of Medical Oncology, University of Washington Medicine, Seattle, WA; Clinical Research Division, Fred Hutch Cancer Research Center, Seattle, WA., Krakow E; Division of Medical Oncology, University of Washington Medicine, Seattle, WA; Clinical Research Division, Fred Hutch Cancer Research Center, Seattle, WA., Rasmussen H; Division of Medical Oncology, University of Washington Medicine, Seattle, WA., Chauncey TR; Division of Medical Oncology, University of Washington Medicine, Seattle, WA; Clinical Research Division, Fred Hutch Cancer Research Center, Seattle, WA; Department of Hospital and Specialty Medicine, Veterans Affairs Puget Sound Health Care System, Seattle, WA., Kanan S; Division of Medical Oncology, University of Washington Medicine, Seattle, WA., Soma L; Department of Pathology, University of Washington Medicine, Seattle, WA., Smith SD; Division of Medical Oncology, University of Washington Medicine, Seattle, WA; Clinical Research Division, Fred Hutch Cancer Research Center, Seattle, WA., Gopal AK; Division of Medical Oncology, University of Washington Medicine, Seattle, WA; Clinical Research Division, Fred Hutch Cancer Research Center, Seattle, WA. Electronic address: agopal@uw.edu.
Publikováno v:
Clinical lymphoma, myeloma & leukemia [Clin Lymphoma Myeloma Leuk] 2021 Mar; Vol. 21 (3), pp. 176-181. Date of Electronic Publication: 2020 Dec 03.
Autor:
Lisberg A; David Geffen School of Medicine at UCLA, Los Angeles, California., Tucker DA; David Geffen School of Medicine at UCLA, Los Angeles, California., Goldman JW; David Geffen School of Medicine at UCLA, Los Angeles, California., Wolf B; David Geffen School of Medicine at UCLA, Los Angeles, California., Carroll J; David Geffen School of Medicine at UCLA, Los Angeles, California., Hardy A; David Geffen School of Medicine at UCLA, Los Angeles, California., Morris K; David Geffen School of Medicine at UCLA, Los Angeles, California., Linares P; David Geffen School of Medicine at UCLA, Los Angeles, California., Adame C; David Geffen School of Medicine at UCLA, Los Angeles, California., Spiegel ML; David Geffen School of Medicine at UCLA, Los Angeles, California., Wells C; David Geffen School of Medicine at UCLA, Los Angeles, California., McKenzie J; David Geffen School of Medicine at UCLA, Los Angeles, California., Ledezma B; David Geffen School of Medicine at UCLA, Los Angeles, California., Mendenhall M; David Geffen School of Medicine at UCLA, Los Angeles, California., Abarca P; David Geffen School of Medicine at UCLA, Los Angeles, California., Bornazyan K; David Geffen School of Medicine at UCLA, Los Angeles, California., Hunt J; David Geffen School of Medicine at UCLA, Los Angeles, California., Moghadam N; David Geffen School of Medicine at UCLA, Los Angeles, California., Chong N; David Geffen School of Medicine at UCLA, Los Angeles, California., Nameth D; David Geffen School of Medicine at UCLA, Los Angeles, California., Marx C; David Geffen School of Medicine at UCLA, Los Angeles, California., Madrigal J; David Geffen School of Medicine at UCLA, Los Angeles, California., Vangala S; David Geffen School of Medicine at UCLA, Los Angeles, California., Shaverdian N; David Geffen School of Medicine at UCLA, Los Angeles, California., Elashoff D; David Geffen School of Medicine at UCLA, Los Angeles, California., Garon EB; David Geffen School of Medicine at UCLA, Los Angeles, California. egaron@mednet.ucla.edu.
Publikováno v:
Cancer immunology research [Cancer Immunol Res] 2018 Mar; Vol. 6 (3), pp. 288-294. Date of Electronic Publication: 2018 Jan 30.